Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185372 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL8078188 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL13875665 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL472020 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL14364969 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL6135633 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL6135412 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL7121023 | 0.90 | TACR1 (0.49) | TACR1NPC1MTORRAB9A | |
| SCHEMBL9537788 | 0.87 | TACR1 (0.46) | TACR1 | |
| SCHEMBL9532928 | 0.87 | TACR1 (0.46) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112557541-B | Detection method of maropiptan citrate and related substances thereof | 河北科技大学 | 2022-07-12 | — | — | CN | disclosed |
| CN-112557541-A | Detection method of maropiptan citrate and related substances thereof | 河北科技大学 | 2021-03-26 | — | — | CN | disclosed |
| EP-1713504-B1 | ANTIMICROBIAL PRESERVATIVES TO ACHIEVE MULTI-DOSE FORMULATION USING BETA-CYCLODEXTRINS FOR LIQUID DOSAGE FORMS | ZOETIS SERVICES LLC (US) | 2017-06-07 | — | — | EP | disclosed |
| US-8183230-B2 | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | PFIZER INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | PFIZER INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1713801-B1 | PROCESS FOR PREPARATION OF 1-(2S,3S)-2-BENZHYDR YL-N-(5-TERT-BUTYL-2-METHOXYBENZYL)QUINUCLIDIN-3-AMINE | PFIZER PROD INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070155697-A1 | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1175417-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | disclosed |
| EP-0690835-A1 | FORMYLATION PROCESS FOR AROMATIC ALDEHYDES | PFIZER INC. (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0668863-A1 | QUINUCLIDINE DERIVATIVE AS SUBSTANCE P ANTAGONIST. | PFIZER (US) | 1995-08-30 | — | — | EP | disclosed |
| EP-0665844-A1 | SUBSTITUTED BENZYLAMINOQUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0655996-A1 | SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES | PFIZER INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994004496-A9 | SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES | — | 1995-01-26 | — | — | WO | disclosed |
| WO-1994024081-A1 | FORMYLATION PROCESS FOR AROMATIC ALDEHYDES | PFIZER INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1994011368-A1 | QUINUCLIDINE DERIVATIVE AS SUBSTANCE P ANTAGONIST | PFIZER INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994008997-A1 | SUBSTITUTED BENZYLAMINOQUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5294744-A | Formylation process for aromatic aldehydes | PFIZER INC. (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1994004496-A1 | SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES | PFIZER INC. (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | NPY1R, HAX1, CBR1 | TACR1 687/4885NPC1 1977/4885MTOR 3395/4885 |
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | CS, GATD3, AQP1 | TACR1 636/4885NPC1 1136/4885MTOR 2073/4885 |
| US-20070155697-A1 | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms | TBCD, CFTR, BTK | TACR1 3742/4885NPC1 110/4885MTOR 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.